The NCRI adjuvant breast cancer (ABC) trial

Completed

• Conditions: Breast cancer; Cancer

• Registration Number: ISRCTN31514446
• Lead Sponsor: Institute of Cancer Research (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2000-04-06
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: Female
• Target Recruitment: 6000

Inclusion Criteria

All women with early invasive breast cancer requiring adjuvant systemic therapy are eligible for the trial providing they have:
1. Early (operable) breast cancer
2. Histological confirmation of invasive carcinoma
3. No previous malignancy (except carcinoma in situ [CIS] cervix or basal cell carcinoma)
4. Received no previous systemic treatment for their disease
5. Given consent and available for subsequent follow-up

Exclusion Criteria

Not provided at time of registration

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The main endpoint used for evaluation of treatment efficacy will be overall survival based on all cause mortality. Relapse-free survival, breast cancer mortality and cardiovascular mortality will also be compared. In a subset of patients there will be a detailed assessment of quality of life. Health economic consequences will also be determined. Ongoing biological predictors of therapeutic response studies, funded by CRUK and BCC.

Secondary Outcome Measures

Name	Time	Method
ot provided at time of registration